Adherence to prophylactic treatment is a critical factor in the control and evolution of patients with hemophilia, as well as in preventing joint damage.
Last October we launched in Europe the study on effectiveness of Medtep Hemophilia platform for patients under prophylactic treatment. The encouraging results of it, which point to a remarkable improvement in adherence to treatment, will be presented at the World Federation of Hemophilia International Congress to be held in Orlando, Florida, next July.
For this reason, and given the project’s success, we have started to take the first steps towards developing a new study on the effectiveness of Medtep platform in terms of prophylactic treatment compliance in patients with hemophilia in the United States.
It’ll be a prospective, randomized, multicentered research project which has the main objective to analyze and assess compliance with pharmacological treatment in patients with hemophilia -teenagers, children and adults- in prophylactic regimen through Medtep platform. In addition, the study will include a cost-effectiveness analysis comparing patients using Medtep Hemophilia to those not using it.
Likewise, it is expected to detect the physical and therapeutic variables that influence the compliance of prophylaxis in patients with hemophilia treated in different hematologic and hemotherapeutic centers in different areas of the United States. Also patients’ quality of life and disease perception will be assessed.
This study does not intend to evaluate any new hemo-derivative product or inhibitor treatment, only the patients’ consequences of using Medtep Hemophilia platform during a certain period of time, which will be compared and contrasted with those who will not be using it. To do this, we will use different types of psychosocial questionnaires based on their scientific evidence and reliability, as well as their specific design for patients with hemophilia. We will also gather the clinical data regarding the joint condition of the patients participating in the study.
Through this project we will be able to identify needs and demands of patients with hemophilia in prophylactic treatment and help address issues which prevent these patients from adhering.
We are confident that, with this study, we’ll be able to demonstrate that continued use of Medtep Hemophilia provides therapeutic possibilities, up to the moment not frequently used amongst this type of patients, and improvements in the therapeutic and preventive treatments. On the other hand, we hope it helps to reduce the high costs of these treatments. Finally, we also expect to show that Medtep improves patients’ quality of life.
Medtep Project Manager
About Medtep Hemophilia
Medtep Hemophilia is the online platform that helps patients with bleeding disorders, such as Hemophilia A, B or Von Willebrand disease, take the next step towards an improved quality of life. The daily routine becomes easier with the help of a calendar about the hemophilia and its treatment, complemented with personalization and follow-up of the healthcare professional.